Papers/PMID:40489293
Efficacy and safety of empagliflozin for the acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.
Annals of medicine2025The record
4 findings · 1 compound · 4 endpoints · 3 null
What it reported
How to read these marksWhat moved
1 finding
empagliflozin — decreases body mass
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Our study demonstrated that empagliflozin had significant effects on the following outcomes in AMI patients: weight reduction (SMD = −0.80, 95% CI = −1.15 to −0.45, p < 0.00001), LVGLS (SMD = −0.27, 95% CI = −0.48 to −0.06, p = 0.01), EF (SMD = 1.01, 95% CI = 0.63–1.38, p < 0.00001), and SBP (SMD = −0.54, 95% CI = −0.88 to −0.20, p = 0.002).”
Quoted verbatim from Efficacy and safety of empagliflozin for the acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Dose
- 10 mg daily in eight included trials, 25 mg daily in one
- Population
- Patients with acute myocardial infarction; pooled RCTs, empagliflozin versus placebo; secondary outcome
Effect -0.8 standardised mean difference, 95% CI -1.15 to -0.45
Efficacy and safety of empagliflozin for the acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.2025PMID:40489293Permalink
What did not
3 findings
empagliflozin — no detected effect on interleukin-6 concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Significant effects of empagliflozin were not noted for the following outcomes: hs-CRP (SMD = −0.29, 95% CI = −0.85 to 0.26, p = 0.30), WBC count (SMD = −0.46, 95% CI = −1.58 to 0.66, p = 0.42), IL-6 (SMD = 0.43, 95% CI = −0.12 to 0.97, p = 0.12), ketone bodies (SMD = 2.95, 95% CI = −1.82 to 7.72, p = 0.23), HbA1c (SMD = −0.05, 95% CI = −0.38 to 0.29, p = 0.79), eGFR (SMD = 0.18, 95% CI = −0.16 to 0.51, p = 0.30), NT-proBNP (SMD = −0.19, 95% CI = −0.59 to 0.21, p = 0.35), E/e’ ratio (SMD = −0.55, 95% CI = −1.54 to 0.44, p = 0.28), TAPSE (SMD = 0.09, 95% CI = −0.12 to 0.30, p = 0.38), and DBP (SMD = −0.27, 95% CI = −0.60 to 0.07, p = 0.12).”
Quoted verbatim from Efficacy and safety of empagliflozin for the acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Dose
- 10 mg daily in eight included trials, 25 mg daily in one
- Population
- Patients with acute myocardial infarction; pooled RCTs, empagliflozin versus placebo; secondary outcome
Effect 0.43 standardised mean difference, 95% CI -0.12 to 0.97
Efficacy and safety of empagliflozin for the acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.2025PMID:40489293Permalink
empagliflozin — no detected effect on C-reactive protein concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Significant effects of empagliflozin were not noted for the following outcomes: hs-CRP (SMD = −0.29, 95% CI = −0.85 to 0.26, p = 0.30), WBC count (SMD = −0.46, 95% CI = −1.58 to 0.66, p = 0.42), IL-6 (SMD = 0.43, 95% CI = −0.12 to 0.97, p = 0.12), ketone bodies (SMD = 2.95, 95% CI = −1.82 to 7.72, p = 0.23), HbA1c (SMD = −0.05, 95% CI = −0.38 to 0.29, p = 0.79), eGFR (SMD = 0.18, 95% CI = −0.16 to 0.51, p = 0.30), NT-proBNP (SMD = −0.19, 95% CI = −0.59 to 0.21, p = 0.35), E/e’ ratio (SMD = −0.55, 95% CI = −1.54 to 0.44, p = 0.28), TAPSE (SMD = 0.09, 95% CI = −0.12 to 0.30, p = 0.38), and DBP (SMD = −0.27, 95% CI = −0.60 to 0.07, p = 0.12).”
Quoted verbatim from Efficacy and safety of empagliflozin for the acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Dose
- 10 mg daily in eight included trials, 25 mg daily in one
- Population
- Patients with acute myocardial infarction; pooled RCTs, empagliflozin versus placebo; secondary outcome
Effect -0.29 standardised mean difference, 95% CI -0.85 to 0.26
Efficacy and safety of empagliflozin for the acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.2025PMID:40489293Permalink
empagliflozin — no detected effect on glycated haemoglobin (HbA1c)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Significant effects of empagliflozin were not noted for the following outcomes: hs-CRP (SMD = −0.29, 95% CI = −0.85 to 0.26, p = 0.30), WBC count (SMD = −0.46, 95% CI = −1.58 to 0.66, p = 0.42), IL-6 (SMD = 0.43, 95% CI = −0.12 to 0.97, p = 0.12), ketone bodies (SMD = 2.95, 95% CI = −1.82 to 7.72, p = 0.23), HbA1c (SMD = −0.05, 95% CI = −0.38 to 0.29, p = 0.79), eGFR (SMD = 0.18, 95% CI = −0.16 to 0.51, p = 0.30), NT-proBNP (SMD = −0.19, 95% CI = −0.59 to 0.21, p = 0.35), E/e’ ratio (SMD = −0.55, 95% CI = −1.54 to 0.44, p = 0.28), TAPSE (SMD = 0.09, 95% CI = −0.12 to 0.30, p = 0.38), and DBP (SMD = −0.27, 95% CI = −0.60 to 0.07, p = 0.12).”
Quoted verbatim from Efficacy and safety of empagliflozin for the acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Dose
- 10 mg daily in eight included trials, 25 mg daily in one
- Population
- Patients with acute myocardial infarction; pooled RCTs, empagliflozin versus placebo; secondary outcome
Effect -0.05 standardised mean difference, 95% CI -0.38 to 0.29
Efficacy and safety of empagliflozin for the acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.2025PMID:40489293Permalink